MutaSeq data for A.10-12
MutaSeq was applied to CD34+ cells from patient samples A.10, A.11 and A.12 of the study. The protocol followed is described in https://doi.org/10.1038/s41467-021-21650-1 and in the methods of the manuscript
- 3 samples
- DAC: EGAC00001003143
- Technology: NextSeq 500
Research use only. Project specific restriction
We will share data for scientific research upon reasonably justified requests. Research with the goal of identifying characteristics of the patient not related to the leukemia (such as surname inference and ancestry research) are excluded. The use of the data for projects not related to cancer research is excluded, exceptions may apply in the context of research aiming to develop new bioinformatics methods. Data cannot be made available to 3rd parties and must be stored in an institutional compute system behind a firewall and without world read access; if stored on portable devices, data must be encrypted. Users must present a signed Data Access Agreement available upon request. Terms of the DAA are not negotiable.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| Other |